Patents by Inventor Christoph Tappertzhofen

Christoph Tappertzhofen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110015400
    Abstract: This invention is directed to processes for the preparation of a compound of the formula I or salt thereof, that is useful as a tryptase inhibitor, to intermediates useful in the preparation of such a compound, to processes for the preparation of such intermediates, and to the use of such intermediates for the preparation of such a compound.
    Type: Application
    Filed: September 30, 2010
    Publication date: January 20, 2011
    Applicants: Sanofi-Aventis Deutschland GmbH, sanofi-aventis US LLC
    Inventors: Claus-Dieter GRAF, Christoph Tappertzhofen, Adam W. Sledeski
  • Patent number: 7825144
    Abstract: The invention is related to a process for preparing compounds of the formula IV by means of conversion of aromatic aldehydes of the formula I using ?-ketoximes of the formula II via N-oxides of the formula III to halomethyloxazoles of the formula IV, wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3, o, n1 and n2 are as defined herein.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: November 2, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Wolfgang Holla, Rolf-Ludwig Hoerlein, Berndt Kulitzscher, Wolfgang Laux, Thomas Stuedemann, Christoph Tappertzhofen, Robert J. H. Scheffer
  • Patent number: 7803950
    Abstract: The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: September 28, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Christophe Salagnad, Frank Zocher, Andreas Burgard, Bernd Junker, Rolf Hoerlein, Thomas Stuedemann, Claus-J├╝gen Maier, Jochen Hachtel, Wolfgang Holla, Christoph Tappertzhofen, Berndt Kulitzscher, Stephane Mutti
  • Publication number: 20090286988
    Abstract: The invention is related to a process for preparing compounds of the formula IV by means of conversion of aromatic aldehydes of the formula I using ?-ketoximes of the formula II via N-oxides of the formula III to halomethyloxazoles of the formula IV, wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3, o, n1 and n2 are as defined herein.
    Type: Application
    Filed: July 27, 2009
    Publication date: November 19, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wolfgang HOLLA, Rolf-Ludwig HOERLEIN, Berndt KULITZSCHER, Wolfgang LAUX, Thomas STUEDEMANN, Christoph TAPPERTZHOFEN, Robert J. H. SCHEFFER
  • Patent number: 7544809
    Abstract: The present invention is comprised of improved methods in the preparation of oxazoles which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: June 9, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Wolfgang Holla, Rolf-Ludwig Hoerlein, Berndt Kulitzscher, Wolfgang Laux, Thomas Stuedemann, Christoph Tappertzhofen, Robert J. H. Scheffer
  • Publication number: 20080114035
    Abstract: The present invention is directed to compounds of Formula III wherein the R1-R7 groups or substituents are defined herein. The present invention also comprises improved methods in the preparation of oxazoles in which the compounds of Formula III are intermediates and which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.
    Type: Application
    Filed: October 30, 2007
    Publication date: May 15, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wolfgang HOLLA, Rolf-Ludwig HOERLEIN, Berndt KULITZSCHER, Wolfgang LAUX, Thomas STUEDEMANN, Christoph TAPPERTZHOFEN, Robert J. H. SCHEFFER
  • Publication number: 20080058529
    Abstract: The present invention is comprised of improved methods in the preparation of oxazoles which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.
    Type: Application
    Filed: May 29, 2007
    Publication date: March 6, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wolfgang HOLLA, Rolf-Ludwig HOERLEIN, Berndt KULITZSCHER, Wolfgang LAUX, Thomas STUEDEMANN, Christoph TAPPERTZHOFEN, Robert SCHEFFER
  • Publication number: 20080051583
    Abstract: The invention relates generally to intermediate compounds derived during the process for preparing diarylcycloalkyl derivatives which are activators for peroxisome proliferator-activated receptors (PPAR activators) and are therefore useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The intermediate compounds of the present invention are defined structurally by the formulae (Ia): and formula (II): wherein the respective substituent groups are defined herein.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 28, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Christophe Salagnad, Frank Zocher, Andreas Burgard, Bernd Junker, Rolf Hoerlein, Thomas Stuedemann, Claus-Jugen Maier, Jochen Hachtel, Wolfgang Holla, Christoph Tappertzhofen, Berndt Kulitzscher, Stephane Mutti
  • Publication number: 20070197788
    Abstract: The present invention relates to a process for preparing chiral non-racemic cis-configured cyclohexanols or cyclohexanol derivatives of the formula (I) Cis-configured hydroxyl-cyclohexane carboxylic acid derivatives of formula (I) are central building blocks or immediate precursors for the medicinally active compounds which allow a therapeutic modulation of the lipid and/or carbohydrate metabolism and are thus suitable for preventing and/or treating type II diabetes, hyperglycemia and artherosclerosis. The cis-configured hydroxyl-cyclohexane carboxylic acid derivatives of formula (I) are central building blocks or immediate precursors for the medicinally active compounds described in the prior art.
    Type: Application
    Filed: January 31, 2007
    Publication date: August 23, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wolfgang Holla, Stefanie Keil, Christoph Tappertzhofen
  • Publication number: 20070197597
    Abstract: This invention is directed to processes for the preparation of a compound of the formula I or salt thereof, that is useful as a tryptase inhibitor, to intermediates useful in the preparation of such a compound, to processes for the preparation of such intermediates, and to the use of such intermediates for the preparation of such a compound.
    Type: Application
    Filed: September 1, 2006
    Publication date: August 23, 2007
    Applicants: Sanofi-Aventis Deutschland GmbH, sanofi-aventis US LLC
    Inventors: Claus-Dieter Graf, Christoph Tappertzhofen, Adam Sledeski
  • Publication number: 20070197614
    Abstract: The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.
    Type: Application
    Filed: February 20, 2007
    Publication date: August 23, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Christophe Salagnad, Frank Zocher, Andreas Burgard, Bernd Junker, Rolf Hoerlein, Thomas Stuedemann, Claus-Jugen Maier, Jochen Hachtel, Wolfgang Holla, Christoph Tappertzhofen, Berndt Kulitzscher, Stephane Mutti